New York, NY -- (SBWIRE) -- 01/06/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Strategic Hotels and Resorts Inc (NYSE:BEE), Targacept , Inc (NASDAQ:TRGT), Gevo, Inc (NASDAQ:GEVO), Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB)
Strategic Hotels and Resorts Inc (NYSE:BEE) showed a volume of 1.13 million shares by the end of last trade whereas the average volume of the stock remained 1.51 million shares. The stock opened the session at $9.41 but then moved to $9.38. At that price, the stock showed a negative performance of -0.32%. Strategic Hotels & Resorts, Inc. (SHR) operates as a self-administered and self-managed real estate investment trust (REIT). As of December 31, 2012, the Company’s portfolio included 18 full-service hotel interests located in urban and resort markets in the United States; Punta Mita, Nayarit, Mexico; Hamburg, Germany, and London, England. SHR conducts its operations through its direct and indirect subsidiaries, including its operating partnership, Strategic Hotel Funding,
Will BEE Get Buyers Even After The Recent Rally? Find Out Here
Targacept , Inc (NASDAQ:TRGT) opened the session at $4.16 and closed the session at $4.09. The stock showed a negative performance of -1.68% in previous trading session. Traded with volume of 1.12 million shares in the prior session and the average volume of the stock remained 489,860.00 shares. Targacept, Inc. is a biopharmaceutical company. The Company is engaged in the design, discovery and development of NNR Therapeutics for the treatment of diseases and disorders of the nervous system. The Company's NNR Therapeutics target neuronal nicotinic receptors (NNRs). As of December 31, 2011, the Company had multiple clinical-stage product candidates and preclinical programs in areas.
Has TRGT Found The Bottom And Ready To Gain Momentum? Find Out Here
Gevo, Inc (NASDAQ:GEVO) opened the session at $1.41 and closed the session at $1.38. The stock showed a negative performance of -2.13% in previous trading session. Traded with volume of 1.11 million shares in the prior session and the average volume of the stock remained 1.85 million shares. Gevo, Inc., is a renewable chemicals and advanced biofuels company. The Company is focused on the development and commercialization of alternatives to petroleum-based products. The Company operates in two segments: Gevo, Inc. Segment and Gevo Development/Agri-Energy Segment. Gevo, Inc. Segment is responsible for all research and development activities related to the future production of isobutanol,
Why Should Investors Buy GEVO After the Recent Fall? Just Go Here and Find Out
Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) traded with volume of 1.10 million shares in the prior session and the average volume of the stock remained 1.55 million shares. The beta of the stock remained 0.62. Navidea Biopharmaceuticals, Inc. (Navidea), formerly Neoprobe Corporation, is a biopharmaceutical company focused on the development and commercialization of precision diagnostic agents. As of December 31, 2011, the Company’s radiopharmaceutical development programs included Lymphoseek (Lymphoseek, Kit for the Preparation of Technetium Tc99m for Injection),
Is NAVB a Solid Investment at These Levels? Read This Report For Details
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)